AbbVie

2 Things Investors Are Missing About AbbVie
2 Things Investors Are Missing About AbbVie
Motley Fool
AbbVie
ABBV-599
Humira
risankizumab
upadacatinib
Imbruvica
Venclexta
Orilissa
Flag link:
Microbiome Report for Week Ending 3/9/19
Microbiome Report for Week Ending 3/9/19
CP Wire
microbiome
Synlogic
AOBiome
AbbVie
Infant Bacterial Therapeutics
IBD
atopic dermatitis
Flag link:
AbbVie’s Humira Remains the Top-Selling Prescription for 2018
AbbVie’s Humira Remains the Top-Selling Prescription for 2018
Biopharma Dive
AbbVie
Humira
prescription data
Flag link:
Principia, AbbVie walk away from 2017 partnership for inflammatory, autoimmune drugs
Principia, AbbVie walk away from 2017 partnership for inflammatory, autoimmune drugs
Endpoints
AbbVie
Principia Biopharma
inflammatory diseases
autoimmune disease
Flag link:
Takeda’s Entyvio Bests Humira in Head-to-Head UC Study
Takeda’s Entyvio Bests Humira in Head-to-Head UC Study
BioSpace
Takeda
Entyvio
AbbVie
Humira
ulcerative colitis
Flag link:
Two big pharma execs share the same challenges, but compensation? They’re not even close
Two big pharma execs share the same challenges, but compensation? They’re not even close
Endpoints
Pharma CEOs
executive pay
AbbVie
Sanofi
Richard Gonzalez
Olivier Brandicourt
Flag link:
Louisiana's 'Netflix' deal for hepatitis C drugs wins bids from AbbVie, Gilead and Merck
Louisiana's 'Netflix' deal for hepatitis C drugs wins bids from AbbVie, Gilead and Merck
Fierce Pharma
hepatitis C
AbbVie
Gilead Sciences
Louisiana
Netflix model
Flag link:
Synlogic Achieves Milestone in Development of Synthetic Biotic for IBD
Synlogic Achieves Milestone in Development of Synthetic Biotic for IBD
CP Wire
Synlogic
inflammatory bowel disease
AbbVie
Flag link:
Synlogic Achieves Milestone in Development of Synthetic Biotic for IBD
Synlogic
inflammatory bowel disease
AbbVie
Flag link:
Genentech Submits sNDA For Venclexta and Gazyva Combo for Chronic Lymphocytic Leukemia
Genentech Submits sNDA For Venclexta and Gazyva Combo for Chronic Lymphocytic Leukemia
CP Wire
Genentech
Roche
AbbVie
chronic lymphocytic leukemia
Gazyva
Venclexta
Flag link:
Genentech Submits sNDA For Venclexta and Gazyva Combo for Chronic Lymphocytic Leukemia
Genentech
Roche
AbbVie
chronic lymphocytic leukemia
Gazyva
Venclexta
Flag link:
AbbVie and Pfizer return to the top of pharma's TV spending list for February
AbbVie and Pfizer return to the top of pharma's TV spending list for February
Fierce Pharma
AbbVie
Humira
Pfizer
Xeljanz
television ads
DTC ads
Flag link:
AbbVie, Akcea benefit from latest CHMP recommendations
AbbVie, Akcea benefit from latest CHMP recommendations
Biopharma Dive
Europe
CHMP
AbbVie
Akcea
Biomarin
Sanofi
Pfizer
drug approvals
Flag link:
Hand over your Humira biosim launch plans; judge tells Boehringer in AbbVie patent fight
Hand over your Humira biosim launch plans; judge tells Boehringer in AbbVie patent fight
Fierce Pharma
AbbVie
Boehringer Ingelheim
Humira
biosimilars
Flag link:
Why Abbvie May Have A Tough Time Defending Humira's Price Before Congress
Why Abbvie May Have A Tough Time Defending Humira's Price Before Congress
Forbes
AbbVie
Humira
drug pricing
Senate
pharma executives
Flag link:
AbbVie’s cancer drug Venclexta blocks diabetes in mice by targeting beta cell ‘senescence’
AbbVie’s cancer drug Venclexta blocks diabetes in mice by targeting beta cell ‘senescence’
Fierce Biotech
senescence
Venclexta
type 1 diabetes
AbbVie
Flag link:
Voyager Shares Take Off on Parkinson's Disease Development Deal
Voyager Shares Take Off on Parkinson's Disease Development Deal
TheStreet.com
Voyager Therapeutics
gene therapy
AbbVie
Parkinson's Disease
Flag link:
The fighter, the saint, and the odd man out: the executives who will defend pharma before Congress
The fighter, the saint, and the odd man out: the executives who will defend pharma before Congress
Stat
drug pricing
US Congress
Donald Trump
Richard Gonzalez
AbbVie
Ken Frazier
Merck
JNJ
Jennifer Taubert
Olivier Brandicourt
Sanofi
Pascal Soriot
AstraZeneca
Giovanni Caforio
Bristol-Myers Squibb
Albert Bourla
Pfizer
Flag link:
Morphic bags J&J as second big pharma partner for oral integrins
Morphic bags J&J as second big pharma partner for oral integrins
Fierce Biotech
JNJ
AbbVie
Morphic Therapeutic
small-molecule integrins
Flag link:
AbbVie’s JAK inhibitor upadacitinib gets Priority Review
AbbVie’s JAK inhibitor upadacitinib gets Priority Review
Pharmaforum
AbbVie
upadacatinib
FDA
priority review
rheumatoid arthritis
Humira
Flag link:

Pages